Emerald Acquisition’s Blueprint Medicines BPMC Stock Holding History

Emerald Acquisition’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$357K	Buy	+12,016	New	+$298K	﹤0.01%	2555

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Emerald Acquisition's BPMC Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Blueprint Medicines (BPMC) in Q3 2016: 12,016 shares worth $357K. The stake represents ﹤0.01% of the portfolio and ranks #2555 among its holdings.

87 funds tracked by Wall St. Rank hold BPMC as of Q3 2016.

Emerald Acquisition held 12,016 shares of Blueprint Medicines worth $357K as of Q3 2016.
Blueprint Medicines was a new Emerald Acquisition position in Q3 2016.
Blueprint Medicines made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2555 holding.
87 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.